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COMMENTARY
Male Infertility and antioxidants: one small 
step for man, no giant leap for andrology?
Sarah J. Martins da Silva*
ABSTRACT
Oxidative stress is detrimental to spermatozoa and is acknowledged to be a common pathology in infertile men. 
Antioxidant supplements, therefore, represent a logical therapeutic approach, although the recent Cochrane review 
recommends cautious interpretation of publications and findings to date. This commentary considers whether 
male fertility supplements have a place in current reproductive medicine practice. Importantly, although sperm 
selection for intracytoplasmic sperm injection is a common research theme, survey data show that men would prefer 
medication to achieve natural conception, rather than treatment to improve assisted reproductive technology (ART) 
success. A total of 27.1% (n = 112), 26.6% (n = 110) and 24.5% (n = 101) respondents indicated they (or their male 
partner) would undertake medical treatment to attempt natural conception for up to 6 months, 12 months and 
2 years, respectively. A total of 63% indicated that they would be prepared to participate in a clinical trial and 57% 
would defer ART by 6 months to do so. This information represents the beginnings of a dialogue with patients and 
stakeholders and should be used to shape research efforts.
Assisted Reproductive Technology (ART) registries consistently document male factor as the most frequent 
underlying or contributory cause 
for infertility worldwide. Despite its 
prevalence, most male factor infertility 
is idiopathic, and generally no cure 
is available. Specifically, no drug that 
can be prescribed to reliably improve 
male fertility, nor added in vitro to 
improve sperm function, is available. 
Therapeutic interventions, therefore, 
rely on ART, which is invasive and 
expensive. ‘Take home baby’ rates after 
intracytoplasmic sperm injection (ICSI) 
remain frustratingly static, with 25–30% 
live birth rate per (fresh) treatment cycle 
(McLernon et al., 2016); despite these 
realities, however, most will seek medical 
intervention and many are prepared to 
face significant financial hardship to pay 
for it. The need for effective treatment 
for male infertility is clearly unmet.
Diagnostic semen analysis is the 
cornerstone of investigation of male 
fertility. It does not, however, evaluate 
sperm function to inform patient 
treatment pathway or prognosis. Sperm 
function tests aim to examine attributes 
required for conception but, although 
they are useful as research tools, they are 
of little clinical benefit, particularly given 
the widespread use of ICSI.
Reactive oxygen species (ROS) are 
by-products of cellular metabolism and 
are essential for normal sperm function, 
including capacitation, hyperactivation, 
acrosome reaction and fertilization. 
Oxidative stress occurs when production 
of ROS exceeds natural antioxidant 
defences, leading to cellular injury. 
Excessive ROS damages the sperm cell 
membrane, which affects sperm motility 
and the ability to fertilize an oocyte, and 
also damages sperm DNA (Aitken and 
Curry, 2011). Key contributors to ROS 
include smoking, obesity and poor diet as 
well as environmental factors, including 
pesticides and pollution.
Spermatozoa are particularly vulnerable 
to oxidative stress because they have 
little cytoplasm and, therefore, limited 
endogenous antioxidant protection. 
Sperm DNA damage caused by ROS 
impairs natural conception, affects 
success of ART and may contribute 
to a higher risk of miscarriage (Simon 
et al., 2017). A variety of approaches 
can be used to test sperm DNA damage 
(Cissen et al., 2016), which are available 
commercially. Analysis is conducted on 
unprepared semen after cryopreservation 
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and shipping. As such, results may be 
arguably different to a fresh semen 
sample, or one prepared for ART. The 
different tests also measure subtly 
different aspects of sperm DNA damage, 
with no defined clinical thresholds, 
although consensus opinion suggests 
that DNA fragmentation index (DFI) 
over 30% is significant. Nonetheless, 
evidence is mounting that DNA repair 
can follow fertilization, and that elevated 
DFI does not necessarily negatively affect 
the outcome of ART (Antonouli et al., 
2019). More frustratingly, rather than 
identifying spermatozoa with low levels of 
DNA damage to select for ICSI, sperm 
DNA damage tests render them clinically 
unusable.
A multitude of alternative approaches 
can be taken to assess oxidative stress. 
Of the four DNA bases, guanine is the 
most susceptible to oxidative damage. 
Levels of 8-hydrodeoxyguanosine 
(8OHdG) can be measured and are 
generally correlated with estimates of 
DNA fragmentation. In human semen, 
ROS can usually be measured by 
fluorescence or chemiluminescence. 
Antioxidant enzymes (superoxide 
dismutase, glutathione, catalase, 
or all three) can be quantified, or a 
combination of ROS and antioxidants 
evaluated, termed oxidation redox 
potential (ORP). Alternatively, oxidative 
balance in semen can be evaluated 
indirectly, e.g. oxygen radical absorbance 
capacity assay. Metabolites of lipid 
oxidative damage can also be quantified, 
including malondialdehyde (MDA) and 
4-hydroxynonenal. Although levels of 
DFI, 8OHdG, ROS, ORP and MDA have 
a degree of agreement, however, this is 
imprecise.
Antioxidants are protective against ROS, 
and those naturally found in semen 
include vitamins C, E, B9 (folic acid), 
trace elements zinc and selenium, and 
micronutrients such as carnitines and 
carotenoids. Perhaps not surprisingly, 
antioxidant supplements have been 
investigated as potential treatments for 
male infertility. The Cochrane meta-
analysis ’Antioxidants for male subfertility’ 
was recently updated and includes 61 
randomized controlled trials and 6264 
infertile men (Smits et al., 2019). It 
concluded that antioxidant therapy was 
associated with an increase in clinical 
pregnancy rate (CPR) and live birth rate 
(LBR). Although this conclusion should 
represent an epic and defining moment 
in clinical andrology, it is not time to 
celebrate just yet, because this review 
has huge and significant limitations. 
Only seven studies (a total of 750 men 
and 124 births) evaluated LBR, and only 
11 trials (786 men, 105 pregnancies) 
evaluated CPR. Evidence demonstrating 
any difference or reduction in 
miscarriage is also insufficient.
Perhaps then, it is somewhat surprising 
that a large variety of commercially 
available vitamin and dietary supplements 
(VDS) are available for male fertility. 
Convenient, prescription-free and non-
invasive, they are increasingly popular 
for men (and women) attempting to 
conceive. Prenatal and pregnancy VDS 
retail value sales grew by 34% between 
2008 and 2013, and currently represent 
a market estimated to be worth 
US$4.7 billion worldwide. Ingredients 
and doses for a representative sample 
of male fertility VDS are shown in the 
TABLE. All contain folic acid (vitamin B9), 
selenium and zinc. Most contain vitamin 
C, vitamin E, or both, and coenzyme 
Q10 and L-carnitine with a variety of 
other trace elements and micronutrients. 
The component amounts, however, are 
substantially lower than those reported 
in scientific publications (Showell et al., 
2014). For example, 15 mg folic acid 
daily for 3 months increased sperm 
count and motility, yet male fertility 
supplements contain 800 µg or less. A 
total of 200 µg selenium daily resulted in 
improved sperm motility, yet 26–150 µg 
is present in VDS. A total of 250 mg 
zinc twice daily had beneficial effects on 
sperm motility and fertilizing capacity, 
yet supplements contain up to 40 mg. 
Intriguingly, magnesium supplementation 
for 3 months showed no association 
with improvement in sperm motility, 
yet several supplements contain it. 
Conversely, 600 mg N-acetyl cysteine 
significantly increased sperm motility 
yet few VDS contain this micronutrient. 
Two fertility supplements in this sample 
contain pine bark extract, also known 
as h. Inclusion of this super-antioxidant 
seems to be based on a study of 19 
male patients in which improvement in 
morphology and mannose binding scores 
is reported in capacitated spermatozoa 
after 90 days’ supplementation (Roseff, 
2002).
Results from published studies of 
combined agents, e.g. zinc and folic acid, 
are disappointingly inconsistent (Showell 
et al., 2014). This presumably reflects the 
heterogeneous population spanned by 
male infertility. It is also possible that a 
threshold of severity exists beyond which 
antioxidant supplementation is unable to 
rescue and reverse. Nonetheless, most 
commercial fertility VDS formulations 
have not been tested in randomized 
controlled trials, and data are limited 
for those that have. For example, the 
effect of FertilAid (Fairhaven Health, 
Bellingham, WA, USA) was studied 
over a 90-day period, but only 14 men 
were included. Total normal motile 
sperm count increased after antioxidant 
supplementation, but this did not reach 
statistical significance (P = 0.05), nor 
were any significant differences found 
in individual semen characteristics 
(Clifton and Ellington, 2009). Profertil 
(LenusPharma, Vienna, Austria) was 
reported to improve fertility in men 
with a 2-year history of unexplained 
subfertility and subclinical varicocele. 
No control group was used, baseline 
semen parameters were all within the 
fertile range according to World Health 
Organization (WHO) diagnostic criteria, 
and no statistical analysis was included 
in the published report (Schauer et al., 
2009). Another study reported improved 
hyaluronan binding after 3 months of 
treatment with Profertil (Lipovac et al., 
2014). Significant pre-existing differences 
were found in hyaluronan binding 
between treatment and control groups at 
baseline (P = 0.02).
Research studies are also needed to 
address relevant study outcomes. 
Fertilovit M Plus supplementation 
(Gonadosan Distribution GmbH, 
Bregenz, Austria) in 160 infertile men 
resulted in a significant improvement in 
all sperm characteristics, but not to a 
point where ICSI could be avoided (Ajayi 
et al., 2013). Men treated for 4 months 
with a single sachet of Proxeed (Sigma-
tau HealthScience, Indianapolis, IN, USA) 
daily showed significant improvement 
in sperm motility, although effect on 
fertility was not assessed (Busetto 
et al., 2012). Alternatively, treatment 
with Profertil for 3 months was found 
to significantly increase sperm motility 
and morphology in 132 subfertile 
males, compared with 73 subfertile 
controls (Imhof et al., 2012). A total of 
34 pregnancies (25.8%) were reported 
in the treatment group, compared with 
11 (15.1%) in the control group, which is 
notable, albeit not statistically significant 
(P = 0.07). Furthermore, Tremellen 
et al. (2007) examined the effect of 
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TABLE INGREDIENTS AND DOSES IN 12 REPRESENTATIVE BRANDS OF COMMERCIALLY AVAILABLE VITAMIN AND 
 DIETARY SUPPLEMENTS FOR MALE FERTILITY
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Acetyl L-carnitine 1.0g
Calcium 20 mg
Chromium 120 µg 20µg 50 µg
Coenzyme Q10 PB 5 mg 15 mg 15 mg 40 mg 15 mg 15 mg 40 mg 30 mg 2 mg
Copper 2 mg 1 mg 1 mg
DHA 65 mg
EPA 90 mg
Garlic oil 333 µg
Ginseng extract PB 30 mg
Glutathione 5 mg 50 mg 80 mg 2.5 mg
Iodine 150 µg
Inositol 40 mg
Iron 5 mg 15 mg 6 mg
L-arginine 300 mg 250 mg 500 mg 250 mg 200 mg 10 mg
L-carnitine PB 100 mg 100 mg 300 mg 500 mg 400 mg 440 mg 440 mg 2.0 g 100 mg 50 mg
L-citrulline 300 mg
L-taurine 100 mg 50 mg 100 mg
Lycopene 4 mg 6 mg a 1.5 mg
Maca extract PB 250 mg
Magnesium 120 mg 20 mg 51 mg 60 mg
Manganese 2 mg 5 mg 0.5 mg
N-acetyl cysteine 50 mg 80 mg 80 mg
Omega 3 FA 170 mg
Pine bark extract 100 mg 30 mg
Selenium 100 µg 100 µg 50 µg 100 µg 60 µg 50 µg 26 µg 80 µg 60 µg 100 µg 100 µg 150 µg
Vitamin A
(beta carotene)
5000 iU 2320 iU
5 mg
3 mg 3 mga 2500 iU
Vitamin B1 1.5 mg 20 mg 12 mg
Vitamin B2 1.7 mg 20 mg 2 mg 5 mg
Vitamin B3 20 mg 20 mg 15 mg 18 mg
Vitamin B5 10 mg 20 mg 10 mg
Vitamin B6 2 mg 20 mg 10 mg 3.5 mg 10 mg 10 mg
Vitamin B7 150 µg
Vitamin B9 500 µg 400 µg 400 µg 500 µg 800 µg 200 µg 500 µg 800 µg 800 µg 400 µg 400 µg 400 µg
Vitamin B12 25 µg 20 µg 9 µg 3 µg 20 µg 75 µg
Vitamin C 250 mg 200 mg 80 mg 100 mg 200 mg 180 mg 100 mg 250 mg 180 mg 100 mg 90 mg
Vitamin D 400 iU 2.5 µg 10 µg 10 µg 1000 iU 600 iU
Vitamin E 150 iU 200 mg 20 mg 100 mg 120 mg 30 mg 400 iU 120 mg 120 mg 150 iU 30 mg
Vitamin K 80 µg
Zinc 30 mg 30 mg 20 mg 25 mg 40 mg 15 mg 25 mg 40 mg 40 mg 20 mg 25 mg 15 mg
a Mixed carotenoids containing beta carotene, lutein and lycopene.
PB, proprietary blend containing L-carnitine, Maca (root), grape seed extract, Asian ginseng (root) and Coenzyme Q10.
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Menevit (Bayer, Pymble NSW) on ART 
outcomes and showed no significant 
differences in oocyte fertilization rate or 
embryo quality between intervention and 
placebo groups. A statistically significant 
improvement in CPR, however, was 
found compared with control.
In summary, routine semen analysis 
can identify those at risk of male factor 
infertility but has limitations. Sperm 
function tests currently have little clinical 
value and treatment options for male 
infertility are almost exclusively limited 
to ART. Despite a wealth of studies 
examining antioxidants, evidence that 
they improve the chance of live birth is 
still insufficient, despite a multitude of 
VDS being commercially marketed for 
this very purpose. A concerted research 
effort is needed to move forward from 
this position.
Involvement of patients and 
stakeholders in research is changing 
and evolving. Public involvement and 
an acknowledgement of the value 
of insight from those who live with a 
health condition are increasingly being 
recognized. Patient contributions will 
be different to expert knowledge but 
help to ensure research quality and 
relevance. To this end, we commissioned 
a SurveyMonkey questionnaire, to 
gather opinion from patients affected 
by male infertility (n = 470). Over 90% 
said that male infertility was equal to or 
more important than female infertility. 
Research into male infertility was rated 
as highly important (average response 
8/10, total score 3726/4700), as was the 
need for development of new treatment 
options. Overwhelmingly, the preferred 
treatment for men (or their partners) 
would be medication (tablets 58.3% 
or injections 24.6%) to achieve natural 
conception rather than medication 
to improve IVF/ICSI success. Similar 
numbers of respondents indicated 
they (or their male partner) would be 
prepared to take treatment for male 
infertility for up to 6 months (27.1%; 
n = 112), up to 12 months (26.6%; 
n = 110) and up to 2 years (24.5%; 
n = 101) to attempt natural conception. 
62.6% (286/457) indicated that they 
would be prepared to participate in a 
clinical trial and 57% (253/444) defer 
IVF/ICSI by 6 months to do so. Not 
surprisingly, live birth was rated as the 
most important outcome after a research 
study (259/467 respondents; 55.5%), 
although pregnancy rate and time to 
achieve pregnancy are also important to 
patients. Miscarriage rate was important 
to 31 out of 467 (6.6%) patients. A 
minority indicated the importance of 
research in generating knowledge to 
help others or to enhance scientific 
understanding.
In conclusion, there is a demand and 
an unmet need for new treatment 
options for male factor infertility, and 
a desire of patients to avoid ART if 
possible. We need better diagnostics 
to identify patients who might benefit 
from intervention and randomized 
controlled trials with outcomes that are 
relevant to patients live birth, time to 
pregnancy, miscarriage and side-effects. 
Results are awaited from NIH funded 
MOXI (males, antioxidants and infertility; 
NCT02421887) and FAZST (folic acid and 
zinc supplementation; NCT01857310) 
trials but current evidence that male 
fertility and live birth really improve after 
antioxidant intake is insufficient, and the 
stark reality remains that no definitive 
treatment to prescribe for idiopathic 
male factor infertility is available.
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